Deciphering the Prognostic Efficacy of MRI Radiomics in Nasopharyngeal Carcinoma: A Comprehensive Meta-Analysis.
Chih-Keng WangTing-Wei WangChia-Feng LuYu-Te WuMan-Wei HuaPublished in: Diagnostics (Basel, Switzerland) (2024)
This meta-analysis investigates the prognostic value of MRI-based radiomics in nasopharyngeal carcinoma treatment outcomes, specifically focusing on overall survival (OS) variability. The study protocol was registered with INPLASY (INPLASY202420101). Initially, a systematic review identified 15 relevant studies involving 6243 patients through a comprehensive search across PubMed, Embase, and Web of Science, adhering to PRISMA guidelines. The methodological quality was assessed using the Quality in Prognosis Studies (QUIPS) tool and the Radiomics Quality Score (RQS), highlighting a low risk of bias in most domains. Our analysis revealed a significant average concordance index (c-index) of 72% across studies, indicating the potential of radiomics in clinical prognostication. However, moderate heterogeneity was observed, particularly in OS predictions. Subgroup analyses and meta-regression identified validation methods and radiomics software as significant heterogeneity moderators. Notably, the number of features in the prognosis model correlated positively with its performance. These findings suggest radiomics' promising role in enhancing cancer treatment strategies, though the observed heterogeneity and potential biases call for cautious interpretation and standardization in future research.
Keyphrases
- contrast enhanced
- lymph node metastasis
- case control
- systematic review
- magnetic resonance imaging
- papillary thyroid
- single cell
- meta analyses
- study protocol
- end stage renal disease
- magnetic resonance
- diffusion weighted imaging
- randomized controlled trial
- squamous cell carcinoma
- public health
- ejection fraction
- chronic kidney disease
- high intensity
- clinical practice
- risk assessment
- peritoneal dialysis
- current status
- free survival
- patient reported
- open label
- phase iii